Answers are grounded in this paper and cite their sources.
Mixed gangliocytoma-pituitary neuroendocrine tumors (GC-PitNETs) are rare pituitary tumors composed of neuroendocrine and gangliocytic elements. Recent studies have demonstrated shared features between neuroendocrine and gangliocytic cells. Specifically, co-expression of neuronal-associated cytoskeletal proteins and pituitary cell lineage transcription factors supports the hypothesis of a common origin of the cells in these tumors. In this multi-institutional study, we characterize the epigenomic profiles of a series of GC-PitNETs by DNA methylation analyses. Twenty-two cases, classified according to the 2022 WHO Classification, were studied including 13 somatotroph, 4 corticotroph, 4 mixed somatotroph-lactotroph, and 1 lactotroph GC-PitNETs. DNA methylation profiles of 21 tumors were analyzed using CNS tumor classifiers (Epignostix Heidelberg v12.8 and NCI Bethesda v 3.1), and unsupervised dimensionality reduction methods. The analysis revealed that all 21 evaluated GC-PitNETs exhibited epigenomic profiles aligning strictly with PitNET/adenoma classes matching their WHO histological diagnoses and showing no epigenomic affiliation with neuronal or glioneuronal reference tumors. These findings indicate that the gangliocytic component of GC-PitNETs lacks a distinct epigenomic signature, supporting the hypothesis that these cells may represent transdifferentiated neuroendocrine cells. Consequently, we propose reclassifying GC-PitNETs within tumors of the anterior pituitary neuroendocrine system and be renamed “pituitary neuroendocrine tumor (subtype) with gangliocytic differentiation.”
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: